Tag: Clinical Trial Phases clinical trial phases

Long-Acting Injectables in Phase 1: Dosing and Safety Challenges

Posted on digi By digi

Long-Acting Injectables in Phase 1: Dosing and Safety Challenges Managing Dose and Safety Complexities in Phase 1 Trials of Long-Acting Injectables Introduction Long-acting injectables (LAIs) are a rapidly growing therapeutic platform offering sustained drug release and improved patient adherence across a range of indications—from mental health and contraception to infectious diseases and metabolic disorders. However,…

Read More “Long-Acting Injectables in Phase 1: Dosing and Safety Challenges” »

Phase 1 (Safety and Dosage)

Handling Multiplicity and Interim Analyses in Phase 2 Trials

Posted on digi By digi

Handling Multiplicity and Interim Analyses in Phase 2 Trials Managing Multiplicity and Interim Analyses in Phase 2 Clinical Trial Design Introduction Phase 2 clinical trials often explore multiple endpoints, treatment arms, biomarkers, or dose levels to evaluate a drug’s efficacy and safety. However, this multidimensional approach can introduce a major statistical issue—multiplicity. When multiple hypotheses…

Read More “Handling Multiplicity and Interim Analyses in Phase 2 Trials” »

Phase 2 (Efficacy and Side Effects)

Bayesian Approaches in Phase 2 Designs

Posted on digi By digi

Bayesian Approaches in Phase 2 Designs Applying Bayesian Methods in Phase 2 Clinical Trial Design Introduction Phase 2 clinical trials are a critical stage for evaluating preliminary efficacy, determining optimal dosing, and making go/no-go decisions. Increasingly, sponsors are turning to Bayesian statistical methods in Phase 2 designs to increase flexibility, incorporate prior knowledge, and optimize…

Read More “Bayesian Approaches in Phase 2 Designs” »

Phase 2 (Efficacy and Side Effects)

Placebo Control in Phase 1: When and Why It’s Used

Posted on digi By digi

Placebo Control in Phase 1: When and Why It’s Used Understanding the Role of Placebos in Phase 1 Clinical Trial Designs Introduction In Phase 1 clinical trials—especially first-in-human studies—the primary goal is to evaluate the safety, tolerability, pharmacokinetics (PK), and sometimes pharmacodynamics (PD) of an investigational drug. While efficacy is not the main objective at…

Read More “Placebo Control in Phase 1: When and Why It’s Used” »

Phase 1 (Safety and Dosage)

Sample Size Calculation for Phase 2 Trials

Posted on digi By digi

Sample Size Calculation for Phase 2 Trials How to Calculate Sample Size for Phase 2 Clinical Trials Introduction Determining the appropriate sample size in a Phase 2 clinical trial is a critical step that directly affects the trial’s ability to detect meaningful treatment effects, avoid underpowered results, and prevent unnecessary exposure of patients to experimental…

Read More “Sample Size Calculation for Phase 2 Trials” »

Phase 2 (Efficacy and Side Effects)

Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment

Posted on digi By digi

Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment Designing Biosimilar Phase 1 Trials: PK, PD, and Immunogenicity Considerations Introduction Biosimilars—biologic products that are highly similar to an approved reference product—must undergo rigorous evaluation to demonstrate similarity in structure, function, and clinical performance. Phase 1 clinical trials are a cornerstone of biosimilar development and…

Read More “Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment” »

Phase 1 (Safety and Dosage)

Recruitment and Retention Strategies in Phase 2

Posted on digi By digi

Recruitment and Retention Strategies in Phase 2 Effective Strategies for Patient Recruitment and Retention in Phase 2 Clinical Trials Introduction Phase 2 clinical trials are critical for evaluating a drug’s efficacy, refining dosage, and identifying early safety signals. Yet, one of the most common reasons for delays and failures in Phase 2 is poor patient…

Read More “Recruitment and Retention Strategies in Phase 2” »

Phase 2 (Efficacy and Side Effects)

Early Stopping Rules in Phase 1 Trials: Safety, PK, and Futility Criteria

Posted on digi By digi

Early Stopping Rules in Phase 1 Trials: Safety, PK, and Futility Criteria Understanding When to Stop: Defining Early Termination Criteria in Phase 1 Trials Introduction Phase 1 clinical trials are designed to explore safety, pharmacokinetics (PK), and tolerability of a new investigational drug. Given the first-in-human exposure and potential unknown risks, early stopping rules are…

Read More “Early Stopping Rules in Phase 1 Trials: Safety, PK, and Futility Criteria” »

Phase 1 (Safety and Dosage)

Real-World Data (RWD) Integration into Phase 2 Design and Interpretation

Posted on digi By digi

Real-World Data (RWD) Integration into Phase 2 Design and Interpretation Integrating Real-World Data (RWD) into Phase 2 Trial Design and Interpretation Introduction As the clinical research landscape evolves, the role of Real-World Data (RWD) is expanding beyond post-marketing surveillance into earlier stages of development—including Phase 2 trials. RWD sources like electronic health records, insurance claims,…

Read More “Real-World Data (RWD) Integration into Phase 2 Design and Interpretation” »

Phase 2 (Efficacy and Side Effects)

Sentinel Dosing Strategy in First-in-Human Trials

Posted on digi By digi

Sentinel Dosing Strategy in First-in-Human Trials Using Sentinel Subjects to Improve Safety in First-in-Human Dose Escalation Trials Introduction First-in-Human (FIH) clinical trials are among the most critical and high-risk stages in drug development. At this point, investigational drugs are administered to humans for the first time, often based only on preclinical data. To mitigate unforeseen…

Read More “Sentinel Dosing Strategy in First-in-Human Trials” »

Phase 1 (Safety and Dosage)